분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-12-22 17:13:05 , Hit : 820
 Editas Expands CRISPR Capabilities through New Technology Licensing


GEN News Highlights
More »
December 19, 2016

Officials at Editas Medicine say they exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR, or clustered regularly interspaced short palindromic repeats, genome-editing system known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

“We are delighted to expand our global CRISPR  genome-editing leadership and to build on the groundbreaking work of these important academic institutions to develop both the new genome-editing system Cpf1 and advanced forms of Cas9,” said Katrine Bosley, president and CEO of Editas Medicine. “With the addition of these significant advancements, we further develop the strongest and most differentiated platform in the fast-moving field of CRISPR, which enables us to design and develop unprecedented genome editing medicines.”

Cpf1 is a CRISPR genome-editing system that has been recently characterized and engineered and may be applied to make medicines for humans, among other applications. According to Bosley, Cpf1 complements the Cas9 genome-editing system because the Cpf1 protein is structurally distinct, has independent intellectual property, and has several potential benefits. Among these are increasing the number of sites in the genome that can be edited, because Cpf1 has distinct protospacer adjacent motifs. The system has simpler manufacture and delivery because the natural system requires only a short, single CRISPR guide RNA and does not include a trans-activating CRISPR RNA (tracrRNA). It also has increased efficiency and accuracy for some forms of gene repair because it makes staggered DNA cuts.

Under the terms of the combined licenses for Cpf1, advanced forms of Cas9, and additional Cas9-based genome-editing technologies from the Broad Institute, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo, Editas Medicine will make total upfront cash payments of $6.25 million and issue a promissory note totaling $10 million that can be settled in stock or cash over a predefined period. In the future, Editas Medicine may make additional payments in cash or stock upon reaching goals and targets related to research and development, commercialization, and market capitalization, and will pay royalties on products based on these technologies.

Bosley also noted that these licenses employ the inclusive innovation model, developed by Broad Institute, Harvard University, and MIT, “which enables Editas Medicine to devote sufficient investment to develop CRISPR-based genome-editing technology to treat human diseases, while enabling broad development of medicines against many diseases.” Under this model, Editas Medicine has a right to exclusively use the technology on targets of its choosing for the development of genomic medicines. After an initial period, other companies may apply.

This past Friday, three developers of treatments based on CRISPR/Cas9 and a company that facilitates nonexclusive licensing of the gene-editing technology said today they have signed a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9. The three developers—CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences—and ERS Genomics entered into the agreement with CRISPR IP co-owners, the Regents of the University of California (UC), Emmanuelle Charpentier, Ph.D., of the Helmholtz Centre for Infection Research, and the University of Vienna.







1107   Dynamic view of the MS genome  이성욱 2010/05/01 2717
1106   Early-Earth cells modeled to show how first life forms might have packaged RNA  이성욱 2012/10/16 2515
  Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 820
1104   Efficient Process Using microRNA Converts Human Skin Cells Into Neurons  이성욱 2011/07/19 2238
1103   Electronics Giant Samsung Makes First Big Biotech Play  이성욱 2013/02/22 3165
1102   EMA panel recommends approval of DAA regimen for patients with HCV  이성욱 2014/11/26 1283
1101   Embryonic stem cells improve vision for two women  이성욱 2012/01/25 2336
1100   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 781
1099   Engineered Viruses Selectively Kill Cancer Cells  이성욱 2011/09/02 2445
1098   Engineering Better Immune Cells  이성욱 2010/05/06 2700
1097   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1147
1096   European regulators back first gene therapy drug  이성욱 2012/07/24 2669
1095   Exosomes Linked to Cancer Spread from Chemoresistant Tumors in Mice  이성욱 2019/01/15 779
1094   Expanding the reach of gene editing with a new CRISPR enzyme  이성욱 2018/10/26 399
1093   Experimental Hepatitis C Drug Shows Promise for Preventing Recurrence in Liver Transplant Patients  이성욱 2013/11/06 2134
1092   Experts find rogue stem cells in liver cancer  이성욱 2011/07/09 2570
1091   Fathers Can Pass Mitochondrial DNA to Children  이성욱 2018/12/26 796
1090   FDA approves 9-valent HPV vaccine for certain cancers  이성욱 2014/12/12 1142
1089   FDA Approves First Gene Therapy for Inherited Disease  이성욱 2017/12/22 512
1088   FDA Approves Gilead CAR-T Therapy Yescarta, Plans Regenerative Medicine Policy 'Soon'  이성욱 2017/10/20 609

[1][2][3][4][5][6][7][8] 9 [10]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN